Molecular Sensors of Estrogen Receptor Conformations and Dynamics

Molecular Endocrinology

Volumn 17, Issue 12, 2003, Pages 2593-2602

  Tamrazi, Anobel ^a   Carlson, Kathryn E ^a   Katzenellenbogen, John A ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CELL NUCLEUS RECEPTOR; DIETHYLSTILBESTROL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR AGONIST; ESTROGEN RECEPTOR ANTAGONIST; ETHYLPYRAZOLE; FLUORESCENT DYE; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PYRAZOLE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

AGONIST; ANISOTROPY; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG ANTAGONISM; FLUORESCENCE; FLUOROPHORE; GENETIC TRANSCRIPTION; HORMONE RECEPTOR INTERACTION; HUMAN; LIGAND BINDING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; SENSOR; SPECTROSCOPY; TARGET CELL;

BINDING SITES; DIMERIZATION; ESTROGEN RECEPTOR ALPHA; FLUORESCENCE POLARIZATION; KINETICS; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, ESTROGEN; RECOMBINANT PROTEINS;

EID: 0348110368     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2003-0239     Document Type: Article

References (52)

1. Cosman F, Lindsay R 1999 Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 20:418-434
2. Jordan VC, Morrow M 1999 Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20:253-278
3. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403
4. Robertson JFR 2001 Faslodex (ICI 182,780), a novel estrogen receptor downregulator - future possibilities in breast cancer. Steroid Biochem Mol Biol 79:209-212
5. Pike ACW, Brzozowski AM, Walton J, Hubbard RE, Thorsell A, Gustafsson JA, Carlquist M 2001 Structural insights into the mode of action of a pure antiestrogen. Structure 9:145-153
6. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson J-A, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
7. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson J, Carlquist M 1999 Structure of the ligand-binding domain of oestrogen receptor β in the presence of a partial agonist and a full antagonist. EMBO J 18:4608-4618
8. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
9. Paige LA, Christensen DJ, Gron H, Norris JD, Gottlin EB, Padilla KM, Chang C, Ballas LM, Hamilton PT, McDonnell DP, Fowlkes DM 1999 Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β. Proc Natl Acad Sci USA 96:3999-4004
10. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
11. Kallenberger BC, Love JD, Chatterjee VKK, Schwabe JWR 2003 A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nature Struct Biol 10:136-140
12. Goldstein SW, Bordner J, Hoth LR, Geoghegan KF 2001 Chemical and biochemical issues related to x-ray crystallography of the ligand-binding domain of Estrogen Receptor α. Bioconjug Chem 12:406-413
13. Koide A, Abbatiello S, Rothgery L, Koide S 2002 Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci USA 99:1253-1258
14. Bramlett KS, Yifei W, Burris TP 2001 Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. Mol Endocrinol 15:909-922
15. Pissios P, Tzameli I, Kushner P, Moore DD 2000 Dynamic stabilization of nuclear receptor ligand-binding domains by hormone or corepressor binding. Mol Cell 6:245-253
16. Metivier R, Stark A, Flouriot G, Hubner MR, Brand H, Penot G, Manu D, Denger S, Reid G, Kos M, Russell RB, Kah O, Pakdel F, Gannon F 2002 A dynamic structural model for estrogen receptor-α activation by ligands, emphasizing the role of interactions between distant A and E domains. Mol Cell 10:1019-1032
17. Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA 2002 Estrogen receptor dimerization: ligand-binding regulates dimer affinity and dimer dissociation rate. Mol Endocrinol 16:2706-2719
18. Mattras H, Aliau S, Richard E, Bonnafous JC, Jouin P, Borgna JL 2002 Identification by MALDI-TOF mass spectrometry of 17α- bromoacetamidopropylestradiol covalent attachment sites on estrogen receptor α. Biochemistry 41:15713-15727
19. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT, Parks DJ, Moore JT, Kliewer SA, Willson TM, Stimmel JB 2002 Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPAR α. Nature 415:813-817
20. Jameson DM, Sawyer WH 1995 Fluorescence anisotropy applied to biomolecular interactions. Methods Enzymol 246:283-300
21. Jameson DM, Seifried SE 1999 Quantification of protein-protein interactions using fluorescence polarization. Methods 19:222-233
22. Pope AJ, Haupt UM, Moore KJ 1999 Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. Drug Discov Today 4:350-362
23. Stauffer SR, Huang YR, Aron ZD, Colleta CJ, Sun J, Katzenellenbogen BS, Katzenellenbogen JA 2001 Triarylpyrazoles with basic side chains: development of pyrazole-based estrogen receptor antagonists. Bioorg Med Chem 9:151-161
24. Hubbard SJ 1998 The structural aspects of limited proteolysis of native proteins. Biochim Biophys Acta 1382: 191-206
25. Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS 2000 Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-α and estrogen receptor-β: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141:3534-3545
26. Seielstad DA, Carlson KE, Kushner PJ, Greene GL, Katzenellenbogen JA 1995 Analysis of the structural core of the human estrogen receptor ligand-binding domain by selective proteolysis/mass spectrometric analysis. Biochemistry 34:12605-12615
27. Seielstad DA, Carlson KE, Katzenellenbogen JA, Kushner PJ, Greene GL 1995 Molecular characterization by mass spectrometry of the human estrogen receptor ligand-binding domain expressed in Escherichia coli. Mol Endocrinol 9:647-658
28. Van Den Bemd G-J, CM, Kuiper GGJM, Pols HAP, Van Leeuwen JPTM 1999 Distinct effects on the conformation of estrogen receptor α and β by both the antiestrogens ICI 164,384 and ICI 182,780 leading to opposite effects on receptor stability. Biochem Biophys Res Commun 261:1-5
29. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW 1995 Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669
30. Stauffer SR, Coletta CJ, Tedesco R, Sun J, Katzenellenbogen BS, Katzenellenbogen JA 2000 Pyrazole ligands: structure-affinity/activity relationships of estrogen receptor-α selective agonists. J Med Chem 43:4934-4947
31. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik CA, Termine JD, Bryant HU 1994 Raloxifene (LY1394881 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63-69
32. Weber G, Farris FJ 1979 Sythesis and spectral properties of a hydrophobic fluorescent probe: 6-propionyl-2-(dimethylamino)naphthalene. Biochemistry 18:3075-3078
33. Prendergast FG, Meyer M, Carlson GL, Iida S, Potter JD 1983 Synthesis, spectral properties, and use of 6-acryloyl-2-dimethylaminonaphthalene (acrylodan). J Biol Chem 258:7541-7544
34. Richieri GV, Ogata RT, Kleinfeld AM 1992 A fluorescently labeled intestinal fatty acid binding protein. J Biol Chem 267:23495-23501
35. Richieri GV, Ogata RT, Kleinfeld AM 1996 Thermodynamic and kinetic properties of fatty acid interactions with rat liver fatty acid-binding protein. J Biol Chem 271:31068-31074
36. Lakowicz JR 1999 Principles of fluorescence spectroscopy. New York: Kluwer Academic/Plenum Publishers
37. Gee AC, Katzenellenbogen JA 2001 Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand-binding and release. Mol Endocrinol 15:421-428
38. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV1998 Ligand-binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 395:137-143
39. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Stembach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV 1999 Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3:397-403
40. Renaud JP, Moras D 2000 Structural studies on nuclear receptors. Cell Mol Life Sci 57:1748-1769
41. Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, Moras D, Renaud JP 2002 Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol Cell 9:303-313
42. Zhou G, Cummings R, Hermes J, Moller DE 2001 Use of homogeneous time-resolved fluorescence energy transfer in the measurement of nuclear receptor activation. Methods 25:54-61
43. Bramlett KS, Burris TP 2002 Effects of selective estrogen receptor modulators (SERMs) on coactivator nuclear receptor (NR) box binding to estrogen receptors. Mol Genet Metab 76:225-233
44. Johnson BA, Wilson EM, Li Y, Moller DE, Smith RG, Zhou G 2000 Ligand-induced stabilization of PPARγ monitored by NMR spectroscopy: Implications for nuclear receptor activation. J Mol Biol 298:187-194
45. Luck LA, Barse JL, Luck AM, Peck CH 2000 Conformational changes in the human estrogen receptor observed by 19F NMR. Biochem Biophys Res Commun 270: 988-991
46. Carlson KE, Choi I, Gee A, Katzenellenbogen BS, Katzenellenbogen JA 1997 Altered ligand-binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry 36:14897-14905
47. Katzenellenbogen JA, Johnson Jr HJ, Myers HN 1973 Photoaffinlty labels for estrogen binding proteins of rat uterus. Biochemistry 12:4085-4092
48. Erijman L, Weber G 1993 Use of sensitized fluorescence for the study of the exchange of subunits in protein aggregates. Photochem Photobiol 57:411-415
49. Runnels LW, Scarlata SF 1995 Theory and application of fluorescence homotransfer to melittin oligomerlzation. Biophys J 69:1569-1583
50. Hamman BD, Oleinikov AV, Jokhadze GG, Traut RR, Jameson DM 1996 Dimer/monomer equilibrium and domain separations of Escherichia coli ribosomal protein L7/L12. Biochemistry 35:16680-16686
51. Hamman BD, Oleinikov AV, Jokhadze GG, Traut RR, Jameson DM 1996 Rotational and conformational dynamics of Escherichia coli ribosomal protein L7/L12. Biochemistry 35:16672-16679
52. Tetin SY, Hazlett TL 2000 Optical spectroscopy in studies of antibody-hapten interactions. Methods 20:341-361